CN113679716B - 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 - Google Patents
溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 Download PDFInfo
- Publication number
- CN113679716B CN113679716B CN202111190625.5A CN202111190625A CN113679716B CN 113679716 B CN113679716 B CN 113679716B CN 202111190625 A CN202111190625 A CN 202111190625A CN 113679716 B CN113679716 B CN 113679716B
- Authority
- CN
- China
- Prior art keywords
- fipv
- bromophenol
- feline
- cats
- infectious peritonitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 bromophenol-pyrazoline compounds Chemical class 0.000 title claims abstract description 33
- 241000725579 Feline coronavirus Species 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 208000005098 feline infectious peritonitis Diseases 0.000 claims description 20
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 13
- 206010034674 peritonitis Diseases 0.000 abstract description 12
- 230000010076 replication Effects 0.000 abstract description 9
- 101800000535 3C-like proteinase Proteins 0.000 abstract description 5
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 11
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 241000711573 Coronaviridae Species 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940125898 compound 5 Drugs 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 1
- 102100027050 Inorganic pyrophosphatase Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
Abstract
Description
Claims (1)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111190625.5A CN113679716B (zh) | 2021-10-13 | 2021-10-13 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
US17/869,819 US11840518B2 (en) | 2021-10-13 | 2022-07-21 | Use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases |
EP22188894.4A EP4166138A1 (en) | 2021-10-13 | 2022-08-04 | Use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111190625.5A CN113679716B (zh) | 2021-10-13 | 2021-10-13 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113679716A CN113679716A (zh) | 2021-11-23 |
CN113679716B true CN113679716B (zh) | 2024-03-26 |
Family
ID=78587603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111190625.5A Active CN113679716B (zh) | 2021-10-13 | 2021-10-13 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11840518B2 (zh) |
EP (1) | EP4166138A1 (zh) |
CN (1) | CN113679716B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848516B (zh) | 2020-08-04 | 2022-04-01 | 山东大学 | 溴酚-吡唑啉类化合物及其合成方法和应用 |
CN112472698B (zh) * | 2020-12-10 | 2022-02-18 | 山东领海生物科技有限公司 | 溴酚-吡唑啉类化合物在治疗猪冠状病毒疾病中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066686A1 (en) * | 2001-02-19 | 2002-08-29 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Feline infectious peritonitis viruses (fipv) diagnosis |
GB0809898D0 (en) * | 2008-06-02 | 2008-07-09 | Univ Ghent | Methods and compositions in the treatment of coronaviruses |
CN109364083A (zh) * | 2018-11-05 | 2019-02-22 | 华中农业大学 | 盐酸考尼伐坦在制备治疗猫传染性腹膜炎药物中的用途 |
CN110063954A (zh) * | 2019-04-10 | 2019-07-30 | 华中农业大学 | Fhpi在制备治疗猫传染性腹膜炎药物中的应用 |
CN110215456A (zh) * | 2019-06-25 | 2019-09-10 | 华中农业大学 | 一种由gc376与gs-441524组成的猫冠状病毒抑制剂组合物 |
CN112472698A (zh) * | 2020-12-10 | 2021-03-12 | 山东领海生物科技有限公司 | 溴酚-吡唑啉类化合物在治疗猪冠状病毒疾病中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135551A1 (de) | 2001-07-20 | 2003-01-30 | Bayer Cropscience Ag | Pyrazolin-Derivate |
RS20090208A (en) | 2006-10-31 | 2010-06-30 | Pfizer Products Inc. | Pyrazoline compounds as mineralocorticoid receptor antagonists |
CA3056072C (en) * | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
CN111848516B (zh) | 2020-08-04 | 2022-04-01 | 山东大学 | 溴酚-吡唑啉类化合物及其合成方法和应用 |
-
2021
- 2021-10-13 CN CN202111190625.5A patent/CN113679716B/zh active Active
-
2022
- 2022-07-21 US US17/869,819 patent/US11840518B2/en active Active
- 2022-08-04 EP EP22188894.4A patent/EP4166138A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066686A1 (en) * | 2001-02-19 | 2002-08-29 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Feline infectious peritonitis viruses (fipv) diagnosis |
GB0809898D0 (en) * | 2008-06-02 | 2008-07-09 | Univ Ghent | Methods and compositions in the treatment of coronaviruses |
CN109364083A (zh) * | 2018-11-05 | 2019-02-22 | 华中农业大学 | 盐酸考尼伐坦在制备治疗猫传染性腹膜炎药物中的用途 |
CN110063954A (zh) * | 2019-04-10 | 2019-07-30 | 华中农业大学 | Fhpi在制备治疗猫传染性腹膜炎药物中的应用 |
CN110215456A (zh) * | 2019-06-25 | 2019-09-10 | 华中农业大学 | 一种由gc376与gs-441524组成的猫冠状病毒抑制剂组合物 |
CN112472698A (zh) * | 2020-12-10 | 2021-03-12 | 山东领海生物科技有限公司 | 溴酚-吡唑啉类化合物在治疗猪冠状病毒疾病中的应用 |
Non-Patent Citations (1)
Title |
---|
猫传染性腹膜炎的治疗;张心怡;;中兽医学杂志;20190315(03);全文 * |
Also Published As
Publication number | Publication date |
---|---|
EP4166138A1 (en) | 2023-04-19 |
CN113679716A (zh) | 2021-11-23 |
US11840518B2 (en) | 2023-12-12 |
US20220363644A1 (en) | 2022-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113679716B (zh) | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 | |
CN103946399B (zh) | 新的噬菌体和包括其的抗菌组合物 | |
CN111172119A (zh) | 具有宽裂解谱的新副溶血弧菌噬菌体、其特异性引物及其应用 | |
EP4014975A1 (en) | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | |
KR20100006574A (ko) | 수산 양식되는 무척추동물의 병원체 감염에 대항하는 합성 레플리킨 펩티드 | |
CN105324481A (zh) | 新颖噬菌体和包括所述新颖噬菌体的抗细菌组成物 | |
CN115175673A (zh) | 双硫仑在抗冠状病毒中的应用 | |
CN113493775A (zh) | 一种猪德尔塔冠状病毒毒株及其应用 | |
CN113491700B (zh) | 牛磺罗定在抗病毒中的应用 | |
CN113201505B (zh) | 一株具备跨种裂解能力的溶藻弧菌噬菌体、其噬菌体组合物及其应用 | |
KR100492455B1 (ko) | 로바타바이러스 억제활성을 갖는 신균주 비피도 박테리움 롱검 에이알81 및 이로부터 분리된 활성단백질 | |
KR102597757B1 (ko) | 천연물 유래 화합물 및 이를 유효성분으로 함유하는 항바이러스제 | |
CN112641789A (zh) | 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用 | |
KR101863593B1 (ko) | 신규한 살모넬라균 특이 박테리오파지 sp1 및 이를 포함하는 항균 조성물 | |
CN101829321A (zh) | 一种预防黄颡鱼红头病的疫苗 | |
CN111363723B (zh) | 新型霍乱弧菌噬菌体及其应用 | |
CN113769077A (zh) | 一种注射用大口黑鲈虹彩病毒灭活疫苗及其制备方法 | |
CN112972476A (zh) | 一种抑制马立克氏病病毒复制、预防或抗马立克氏病的药物 | |
CN113368141A (zh) | 一种防治猪囊膜病毒感染性疾病的药物组合物及制备方法和植物提取物的应用 | |
CN111073863A (zh) | 猪流行性腹泻、猪德尔塔冠状病毒二联弱毒疫苗及其制备方法 | |
CN114015598B (zh) | 分离自藏灵菇的乳酸片球菌及其在防治轮状病毒感染中的应用 | |
CN112522217B (zh) | 一种犬瘟热弱毒株及其制备的疫苗组合物和应用 | |
CN113876751B (zh) | 竹红菌乙素在制备防治非洲猪瘟的药物中的应用 | |
CN114958780B (zh) | 一种牛Aichivirus D病毒分离株及其应用 | |
CN116139155A (zh) | 黎芦碱及黎芦提取物在制备抗病毒药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240204 Address after: No. 53 Xiaogang Second Road, Shibei District, Qingdao City, Shandong Province, 266005, Xiaogang Mingcheng Phase I, 5-1-401 Applicant after: Shi Dayong Country or region after: China Applicant after: Tian Yang Address before: 264309 incubation center, Muyun West Road, Gangwan street, Rongcheng City, Weihai City, Shandong Province Applicant before: Shandong Linghai Biotechnology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |